drugset
drugset / Trial / NCT04665986

Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer

NCT04665986 ↗

Phase 3 Unknown 50 enrolled Zhejiang Cancer Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a randomized, double-blind multicenter Phase III study for evaluating the efficacy of neoadjuvant Navelbine plus trastuzumab and Pertuzumab versus Docetaxel plus trastuzumab and Pertuzumab given as neoadjuvant treatment in HER2 positive early-stage or locally advanced breast cancer.

Timeline

Start
2021-03-01
Primary completion
2022-02-28
Completion
2023-02-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Docetaxel Small molecule 90 mg/m2 —
Subject Vinorelbine Small molecule 25 mg/m2 —

Indications

breast cancer